Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Oncotarget. 2020 Apr 7;11(14):1289. doi: 10.18632/oncotarget.27407.

Authors

Sunkyu Kim¹, Ralph Tiedt², Alice Loo¹, Thomas Horn¹, Scott Delach¹, Steven Kovats¹, Kristy Haas¹, Barbara Schacher Engstler², Alexander Cao¹, Maria Pinzon-Ortiz¹, Iain Mulford¹, Michael G Acker¹, Rajiv Chopra³, Christopher Brain⁴, Emmanuelle di Tomaso¹, William R Sellers¹, Giordano Caponigro¹

Affiliations

¹ Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA.
² Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland, USA.
³ Novartis Institutes for BioMedical Research, Chemical Biology & Therapeutics, Cambridge, MA, USA.
⁴ Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Cambridge, MA, USA.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.26215.].

Copyright: © 2019 Kim et al.

Publication types

Published Erratum